GSK plc
NYSE:GSK Rapport sur les actions
Capitalisation boursière : US$70.6b
Ajouter à la liste de surveillanceGSK Croissance future
Future contrôle des critères 4/6 GSK devrait augmenter ses bénéfices et son chiffre d'affaires de 22.4% et de 3.9% par an respectivement. Le BPA devrait croître de de 22.1% par an. Le rendement des capitaux propres devrait être 28.7% dans 3 ans.
Informations clés
22.4%
Taux de croissance des bénéfices
22.1%
Taux de croissance du BPA
Pharmaceuticals croissance des bénéfices 24.0% Taux de croissance des recettes 3.9% Rendement futur des capitaux propres 28.7% Couverture par les analystes Good
Dernière mise à jour 13 Nov 2024
Mises à jour récentes de la croissance future
Afficher toutes les mises à jour
GSK Q3 Earnings Preview: Shingrix And Arexvy Make The Stock A 'Strong Buy' Oct 26
GSK plc Announces New Positive Arexvy Data in Younger Adults At Risk Oct 24
GSK plc Announces US Food and Drug Administration Accepts New Drug Application for Treatment of Uncomplicated Urinary Tract Infections in Female Adults and Adolescents Oct 16
GSK plc Announces Positive Headline Results from the Phase III Clinical Trials ANCHOR-1 and ANCHOR-2 Oct 14 Roche/Genentech's Gazyva Poised to Transform Lupus Nephritis Treatment After Positive Phase III Results
GSK plc Presents Positive Data for Arexvy, its Respiratory Syncytial Virus Vaccine Oct 08 Gsk Plc's Menveomeningococcal Vaccine in New Single-Vial, Fully Liquid Presentation Receives Positive European Chmp Opinion Sep 24
GSK plc Reaches Two Confidential Settlements in Cases Filed in California State Court with John Russell Sep 19
GSK plc Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX Sep 18
GSK plc Announces Positive Headline Results of A Phase Ii Trial (Nct06431607) for Its Mrna Seasonal Influenza Vaccine Programme Sep 13
GSK plc Reaches Confidential Settlement in Zantac Litigation with Isaac Dixon Sep 12
GSK plc Provides Update on Phase I/II Therapeutic Herpes Simplex Virus Vaccine Trial Sep 11
GSK plc Announces European Commission Has Authorised Arexvy for Active Immunisation for the Prevention of Lower Respiratory Tract Disease Aug 29 GSK plc Announces Zantac (Ranitidine) Litigation Update
GSK's Q2 Success Amid Challenges: What Investors Need To Know Aug 26 GSK plc Receives US Food and Drug Administration Breakthrough Therapy Designation for GSK5764227 Aug 20
Gsk plc Announces Zantac (Ranitidine) Litigation Update Aug 16
GSK plc Announces Zantac (Ranitidine) Litigation Update Aug 06
GSK plc Announces US FDA Expands Jemperli (Dostarlimab-Gxly) Plus Chemotherapy Approval to All Adult Patients with Primary Advanced or Recurrent Endometrial Cancer as the First and Only Immuno-Oncology-Based Treatment to Show an Overall Survival Benefit Aug 02
GSK: Good Earnings Report, But Risks Ahead (Rating Downgrade) Jul 31 GSK plc Declares Second Interim Dividend for Second Quarter of 2024, Payable on 10 October 2024 Jul 31
GSK plc Announces Blenrep EMA Filing Acceptance Jul 22
GSK plc Begins Shipping Influenza Vaccine Doses for 2024-25 Season Jul 12
GSK's Omjjara (Momelotinib) Receives Approval in Japan for Treatment of Myelofibrosis iTeos Therapeutics, Inc. and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer Jun 18
GSK plc Announces That the US Food and Drug Administration (FDA) Has Approved Arexvy Jun 13
GSK plc (LSE:GSK) acquired Elsie Biotechnologies for $50 million. Jun 08 GSK plc Announces Positive Results from an Interim Analysis of the DREAMM-8 Phase III Head-To-Head Trial Evaluating Belantamab Mafodotin Jun 05
GSK plc Provides Litigation Update May 25
GSK Breathes New Life Into Asthma Treatment With Depemokimab May 22 An unknown buyer intended to acquire 4.2% stake in Haleon plc (LSE:HLN) from GSK plc (LSE:GSK) for £1.2 billion. May 18
GSK Announces Intention to Sell Approximately 385 Million Shares in Haleon Gsk plc Announces Board Committee Changes May 09
GSK plc to Report Q2, 2024 Results on Jul 31, 2024 May 03 GSK plc Announces the US Food and Drug Administration Accepted the Supplemental Biologics License Application for Jemperli Apr 24
GSK plc Announces Positive Results from the Pivotal Eagle-1 Phase III Trial for Gepotidacin GSK plc Announces US Food and Drug Administration Accepts for Review Biologics License Application for its 5-in-1 Meningococcal ABCWY (MenABCWY) Vaccine Candidate Apr 16
GSK plc, Annual General Meeting, May 08, 2024 Mar 26 GSK plc Appoints Hal Dietz as Member of Nominations & Corporate Governance Committee, Effective 11 March 2024 Mar 09
GSK plc Announces Positive Headline Results from an Interim Analysis of the Dreamm-8 Phase Iii Head-To-Head Trial Evaluating Blenrep (Belantamab Mafodotin) Mar 08
GSK plc Reaches a Confidential Settlement with Boyd/Steenvoord GSK plc (LSE:GSK) completed the acquisition of Aiolos Bio, Inc. from a group of shareholders. Feb 15
GSK plc Receives US Food and Drug Administration Fast Track Designation for Bepirovirsen in Chronic Hepatitis B Feb 14
Center for Drug Evaluation Accepts to Review GSK's Regulatory Application for Shingrix for the Prevention of Shingles in at-Risk Adults Aged 18 and over Feb 07 Gsk plc Announces Results from an Interim Analysis of The DREAMM-7 Phase III Head-To-Head Trial
GSK plc to Report Q1, 2024 Results on May 01, 2024 Feb 02
Prévisions de croissance des bénéfices et des revenus NYSE:GSK - Estimations futures des analystes et données financières antérieures (GBP Millions ) Date Recettes Les revenus Flux de trésorerie disponible Cash from Op Moy. Nombre d'analystes 12/31/2026 34,338 6,487 6,489 9,537 16 12/31/2025 32,451 5,802 5,615 8,483 17 12/31/2024 31,271 3,544 3,962 6,617 17 9/30/2024 31,311 2,511 4,917 7,421 N/A 6/30/2024 31,446 4,033 5,222 7,479 N/A 3/31/2024 30,740 4,484 5,330 7,673 N/A 12/31/2023 30,328 4,928 4,436 6,768 N/A 9/30/2023 29,652 6,078 3,247 5,477 N/A 6/30/2023 29,334 5,373 2,486 4,586 N/A 3/31/2023 29,085 4,455 2,892 4,914 N/A 12/31/2022 29,324 4,461 5,341 7,403 N/A 9/30/2022 29,024 3,387 7,620 9,265 N/A 6/30/2022 27,822 3,505 8,073 10,506 N/A 3/31/2022 26,731 4,013 7,611 10,163 N/A 12/31/2021 24,696 3,316 5,939 7,952 N/A 9/30/2021 26,359 3,567 6,064 8,040 N/A 6/30/2021 28,378 3,934 4,871 6,339 N/A 3/31/2021 30,164 4,983 7,028 7,807 N/A 12/31/2020 24,354 4,873 6,839 8,441 N/A 9/30/2020 34,259 6,371 6,833 8,039 N/A 6/30/2020 34,998 6,679 8,751 9,693 N/A 3/31/2020 35,183 5,380 6,628 8,322 N/A 12/31/2019 33,754 4,645 6,261 8,020 N/A 9/30/2019 33,052 4,561 6,832 8,686 N/A 6/30/2019 31,759 4,427 6,488 8,248 N/A 3/31/2019 31,260 3,904 6,735 8,221 N/A 12/31/2018 30,821 3,623 6,881 8,421 N/A 9/30/2018 30,263 1,862 5,521 7,171 N/A 6/30/2018 30,014 1,656 N/A 6,991 N/A 3/31/2018 30,024 1,035 N/A 6,637 N/A 12/31/2017 30,186 1,532 N/A 6,918 N/A 9/30/2017 30,133 2,335 N/A 7,040 N/A 6/30/2017 29,832 1,931 N/A 6,910 N/A 3/31/2017 29,044 1,676 N/A 7,138 N/A 12/31/2016 27,889 912 N/A 6,497 N/A 9/30/2016 26,589 301 N/A 5,007 N/A 6/30/2016 25,174 31 N/A 3,721 N/A 3/31/2016 24,530 615 N/A 2,702 N/A 12/31/2015 23,923 8,422 N/A 2,569 N/A 9/30/2015 23,823 9,809 N/A 3,278 N/A 6/30/2015 23,342 9,672 N/A 4,070 N/A 3/31/2015 23,015 10,177 N/A 4,619 N/A 12/31/2014 23,006 2,756 N/A 5,176 N/A 9/30/2014 23,726 4,184 N/A 5,153 N/A 6/30/2014 24,590 4,752 N/A 5,957 N/A 3/31/2014 25,647 5,143 N/A 6,902 N/A 12/31/2013 26,505 5,436 N/A 7,222 N/A
Afficher plus
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de GSK ( 22.4% par an) est supérieure au taux d'épargne ( 2.6% ).
Bénéfices vs marché: Les bénéfices de GSK ( 22.4% par an) devraient croître plus rapidement que le marché US ( 15.5% par an).
Croissance élevée des bénéfices: Les bénéfices de GSK devraient augmenter de manière significative au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de GSK ( 3.9% par an) devrait croître plus lentement que le marché de US ( 8.9% par an).
Croissance élevée des revenus: Le chiffre d'affaires de GSK ( 3.9% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de GSK devrait être élevé dans 3 ans ( 28.7 %)
Découvrir les entreprises en croissance Simply Wall St™ Simply Wall Street Pty Ltd Level 7, 320 Pitt Street, Sydney Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}